Instrumental activities of daily living test could ID Alzheimer’s disease
Jun 28, 2023
An association was found between simulated real-life IADL and interactions of amyloid and early tau accumulation in cognitively normal seniors.
Experimental drug for Alzheimer’s disease slows decline in thinking
May 03, 2023
Eli Lilly says the drug slows memory and thinking declines in early symptomatic Alzheimer’s disease patients by more than a third.
Second death in trial of experimental Alzheimer’s drug raising concerns
Nov 29, 2022
Doctors suspect that by stripping away amyloid deposits, lecanemab weakens blood vessels and leaves them vulnerable to bleeds.
Transcranial direct current stimulation beneficial in Alzheimer’s disease
Dec 07, 2023
Active tCDS improves cognitive functions in memory domain, including word recall, recall of test instructions and word recognition.
Firearm-owning veterans receptive to safety discussions in routine care
Jul 03, 2023
The findings are based on a survey encompassing six clinical contexts involving heightened risk for firearm injury.
Intranasal insulin may have pro-cognitive benefits
Jun 30, 2023
Improvement in global cognition was seen for patients with Alzheimer’s disease/mild cognitive impairment, but no effects were seen for healthy individuals or other patient populations.
Social isolation tied to wide variety of dementia risk factors
Feb 02, 2023
Social isolation may be a modifiable risk factor for preventing Alzheimer’s disease-related dementias, authors say.
Tau PET performs well in predicting dementia in individuals with MCI
Jun 12, 2024
Tau positron emission tomography predicts all-cause dementia and Alzheimer disease dementia
FDA delays decision on new Alzheimer’s drug
Mar 08, 2024
Instead of approving the new Alzheimer’s drug donanemab this month, as was expected, the U.S. Food and Drug Administration will now require the experimental medication be scrutinized more closely...
Monoclonal antibodies provide small benefits in Alzheimer’s disease
Jan 26, 2024
Harms include increased risks for amyloid-related imaging abnormalities (ARIA)-edema, ARIA-hemorrhage and symptomatic ARIA-edema.